Bioxyne Ltd Announces General Meeting for Name Change and Capital Consolidation
Key points
- Bioxyne Ltd to change its name to BLS Pharmaceuticals Limited
- Capital consolidation on a 10:1 basis
- General Meeting scheduled for June 19, 2026 at 2:00 pm (Sydney time)
- Voting details and proxy forms provided in the announcement
Full summary
Bioxyne Ltd (ASX:BXN) has announced a General Meeting to be held on Friday, June 19, 2026, at 2:00 pm (Sydney time) at the office of Addisons at Level 9, 2 Park Street, Sydney NSW 2000. The meeting will consider two resolutions: the first being a special resolution to change the company's name to BLS Pharmaceuticals Limited, and the second being an ordinary resolution to consolidate the issued capital on a 10:1 basis. Shareholders are encouraged to vote by proxy, with proxy forms available online or via email. The name change will take effect upon ASIC's alteration of the company's registration details, and the capital consolidation will not affect shareholders' voting interests.
Guidance
Bioxyne Ltd plans to change its name to BLS Pharmaceuticals Limited and consolidate its capital on a 10:1 basis.
Outlook
The company anticipates that the name change and capital consolidation will better reflect its future operations and branding.
Summary generated by a large language model. Please interpret with care.